• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MA stargazing reveals a different story

Publication
Article
MHE PublicationMHE December 2020
Volume 30
Issue 12

All the Medicare Advantage trend lines seem like they are northward bound. Enrollment, the number of plans, the number of companies selling those plans — they’re all up. So Avalere Health’s report last month on the percentage of beneficiaries in highly rated plans stood out — and not in a good way.

All the Medicare Advantage trend lines seem like they are northward bound. Enrollment, the number of plans, the number of companies selling those plans — they’re all up. So Avalere Health’s report last month on the percentage of beneficiaries in highly rated plans stood out — and not in a good way.

Related: Medicare Advantage Enrollment Keeps Growing

CMS’ Star Rating program grades the quality of Medicare Advantage plans on a scale of 1 to 5 stars, with 5 being the highest quality.

Using data that the CMS made available in October, Avalere Health calculated that approximately 11.9% of the enrollees in Medicare Advantage plans that include drug coverage are in 5-star plans, which isn’t a big difference from the 11% of enrollees in 5-star plans last year.

But the consulting firm’s numbers show that the proportion of enrollees in 4.5-star plans dropped sharply, from 31.4% last year to 19.6% this year, and the proportion in 4-star plans dipped from 38.8% last year to 30.9% this year.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.